Home>Topics>Stocks>Alexion Pharmaceuticals

Alexion Pharmaceuticals ALXN

  1. All
  2. Commentary
  3. Headlines
    1. Alexion Pharmaceuticals ( ALXN ) Q3 2014 Results - Earnings Call Webcast

      Headlines

      Thu, 23 Oct 2014

      Alexion Pharmaceuticals ( ALXN ) Q3 2014 Results - Earnings Call Webcast

    2. UPDATE 1-Alexion Pharma quarterly adj profit beats, raises forecast again

      Headlines

      Thu, 23 Oct 2014

      Oct 23 (Reuters) - Alexion Pharmaceuticals Inc reported a better-than-expected adjusted quarterly profit on strong sales of its blood disorder drug Soliris and raised its full-year profit forecast for the fourth time this year.

    3. Alexion Pharma quarterly adj profit beats, raises forecast again

      Headlines

      Thu, 23 Oct 2014

      Oct 23 (Reuters) - Alexion Pharmaceuticals Inc reported a better-than-expected adjusted profit on strong sales of its blood disorder drug Soliris and raised its full-year profit forecast for the fourth time this year.

    4. Alexion Pharmaceuticals beats by $0.11, beats on revenue

      Headlines

      Thu, 23 Oct 2014

      Alexion Pharmaceuticals beats by $0.11, beats on revenue

    5. End Of The Year Events To Drive Some Of October's Beaten Up Biotech Companies

      Headlines

      Mon, 20 Oct 2014

      chance, to drive these companies stock prices considerably through the rest of the year and beyond. Alexion Pharmaceuticals (NASDAQ: ALXN ) Alexion is a biopharmaceutical company that discovers, develops and commercializes medicines for

    6. Alexion submits NDA in Japan for asfotase alfa

      Headlines

      Wed, 15 Oct 2014

      Alexion Pharmaceuticals (NASDAQ: ALXN ) submits a New Drug Application to the Japanese Ministry of Health, Labour and Welfare for asfotase alfa , an enzyme replacement

    7. Alexion to report on October 23

      Headlines

      Thu, 9 Oct 2014

      Alexion Pharmaceuticals ( ALXN -1.2% ) will report Q3 results on October 23 before the open. The conference call will begin at 10:00 am ET. Consensus view is EPS of $1.16 on revenues of $542M. Post your comment!

    8. Alexion names new chairman

      Headlines

      Thu, 9 Oct 2014

      Alexion Pharmaceuticals (NASDAQ: ALXN ) appoints Leonard Bell, M.D., Chairman of the Board replacing the recently-deceased Max Link, Ph.D. Dr. Bell is the principal founder of the company. Post your comment!

    9. Alexion Chairman passes suddenly

      Headlines

      Tue, 7 Oct 2014

      Alexion Pharmaceuticals ( ALXN -3.3% ) Chairman Max Link, Ph.D., died unexpectedly on October 5 while on a business trip. He was 74 years old. The BOD will announce a new chairman shortly. Post your comment!

    10. Encouraging Phase 2 results for Alexion's asfotase alfa

      Headlines

      Fri, 19 Sep 2014

      Alexion Phharmaceuticals (NASDAQ: ALXN ) presented data from two Phase 2 studies of asfotase alfa earlier today at the European Society for Pediatric Endocrinology Meeting

    « Prev12345Next »
    Content Partners